Login with Linked

Follow us on

Link Linkedin Youtube

Attruby

Attruby is an oral tablet for adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary). It stabilizes misfolded transthyretin proteins, reducing the risk of heart-related death and hospitalization.

Molecule Details :

  • Molecule Name :

    Acoramidis

  • Innovator :

    BRIDGEBIO PHARMA INC

  • Approval Date :

    22-Nov-24

  • NCE-1 Date :

    22-Nov-28

  • Dosage Form :

    Oral Tablets

  • Strength :

    356 mg

  • Therapeutic Category :

    Cardiovascular Agents

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    283

  • 2026 :

    734

  • 2027 :

    1,240

  • 2028 :

    1,731

  • 2029 :

    2,084

  • 2030 :

    2,513

  • 2031 :

    2,898
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?